Such a bold, exceedingly rare move shocked investors, although not everyone condemned the decision. One analyst called deSouza a "maverick," while an unnamed investor told the Financial Times that Grail was a "natural extension" of Illumina's technology. Still, the consensus was that the gamble would be ruinous. Details about the Galleri test's promise, the size of the future cancer diagnostic market, and deSouza's financial judgment were all lost in the flap. Grail had become a distraction, analysts complained. Eventually, the legal melee would weigh on Illumina's once-soaring share price, which would fall more than 60% before Icahn joined the brawl.